Summary
Objective. To retrospectively determine the relationship of age to toxicity from adjuvant chemotherapy for breast cancer.
Design and Methods We identified 1405 consecutive patients age 65 or older with primary invasive breast cancer who were seen at Memorial Sloan-Kettering Cancer Center from January 1998 to December 2000. Patients selected from this cohort for analysis were aged 65 or older at diagnosis; received their follow-up care at Memorial Sloan-Kettering Cancer Center; had stage I, II, or III breast cancer; and received adjuvant chemotherapy consisting of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil), an anthracycline-based regimen (AC [doxorubicin and cyclophosphamide], or AC-T [AC and paclitaxel or docetaxel]). Exclusion criteria included prior chemotherapy or previous breast cancer.
Results. One hundred thirty-two patients were included in this study, with a mean age of 70 (range 65–79). Comorbidity measured by the Charlson comorbidity index was low: score 0 (83%), 1 (12%), 2 (5%); with stages: I(18%), IIA (41%), IIB (27%), IIIA (8%), IIIB (6%), T1Nx (1%). Patients receiving an anthracycline-based regimen were more likely to experience grade 3 or 4 toxicity (p=0. 01), require hospitalization (p<0.001), and/or develop febrile neutropenia (p<0.001). Treatment delays due to myelosuppression occurred more frequently in patients receiving CMF (p<0.001). The type of chemotherapy regimen (anthracycline compared to CMF) was a better predictor for toxicity than increased age or comorbidity score.
Conclusions. In this cohort of older patients with breast cancer, the risk for toxicity from adjuvant chemotherapy depended more on the type of regimen (anthracycline vs. CMF) than the patient’s chronological age.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AC:
-
(doxorubicin and cyclophosphamide)
- AC-T:
-
(AC and paclitaxel or docetaxel)
- CALGB:
-
Cancer and Leukemia Group B
- CMF:
-
(cyclophosphamide, methotrexate, and 5-fluorouracil)
References
A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thun (2004) ArticleTitleCancer Statistics, 2004 CA Cancer J Clin 54 IssueID1 8–29
K Armstrong A Eisen B Weber (2000) ArticleTitleAssessing the risk of breast cancer N Engl J Med 342 IssueID8 564–571
R Yancik (1997) ArticleTitleCancer burden in the aged: an epidemiologic and demographic overview Cancer 80 IssueID7 1273–1283
PA Newcomb PP Carbone (1993) ArticleTitleCancer treatment and age: patient perspectives J Natl Cancer Inst 85 IssueID19 1580–1584
E Busch M Kemeny A Fremgen RT Osteen DP Winchester RE Clive (1996) ArticleTitlePatterns of breast cancer care in the elderly Cancer 78 IssueID1 101–111
CJ Newschaffer L Penberthy CE Desch SM Retchin M Whittemore (1996) ArticleTitleThe effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer Arch Intern Med 156 IssueID1 85–90
L Bergman G Dekker FE Leeuwen Particlevan SJ Huisman FS Dam Particlevan JA Dongen Particlevan (1991) ArticleTitleThe effect of age on treatment choice and survival in elderly breast cancer patients Cancer 67 IssueID9 2227–2234
R Yancik LG Ries JW Yates (1989) ArticleTitleBreast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival Cancer 63 IssueID5 976–981
BE Hillner L Penberthy CE Desch MK McDonald TJ Smith SM Retchin (1996) ArticleTitleVariation in staging and treatment of local and regional breast cancer in the elderly Breast Cancer Res Treat 40 IssueID1 75–86
R Ballard-Barbash AL Potosky LC Harlan SG Nayfield LG Kessler (1996) ArticleTitleFactors associated with surgical and radiation therapy for early stage breast cancer in older women J Natl Cancer Inst 88 IssueID11 716–726
A Hurria D Leung K Trainor P Borgen L Norton C Hudis (2003) ArticleTitleFactors influencing treatment patterns of breast cancer patients age 75 and older Crit Rev Oncol Hematol 46 IssueID2 121–126
XL Du C Osborne JS Goodwin (2002) ArticleTitlePopulation-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer J Clin Oncol 20 IssueID24 4636–4642
L Balducci M Extermann (2000) ArticleTitleManagement of cancer in the older person: a practical approach Oncologist 5 IssueID3 224–237
Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132): 930–942, 1998
H Herbsman J Feldman J Seldera B Gardner AE Alfonso (1981) ArticleTitleSurvival following breast cancer surgery in the elderly Cancer 47 IssueID10 2358–2363
Muss HB, Berry DA, Weiss RB, Budman DR, Wood WC, Henderson CI, Hudis C, Winer EP, Norton L: Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (Adj) as younger patients (pts): The Cancer and Leukemia Group B (CALGB) experience [abstract]. Am Soc Clin Oncol 2003. Abstract 11
ME Charlson P Pompei KL Ales CR MacKenzie (1987) ArticleTitleA new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 IssueID5 373–383
M Extermann L Balducci GH Lyman (2000) ArticleTitleWhat threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 18 IssueID8 1709–1717
Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114): 1451–1467, 1998
L Balducci J Yates (2000) ArticleTitleGeneral guidelines for the management of older patients with cancer Oncology (Huntingt) 14 IssueID11A 221–227
EC Dees S O’Reilly SN Goodman S Sartorius MA Levine RJ Jones LB Grochow RC Donehower JH Fetting (2000) ArticleTitleA prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer Cancer Invest 18 IssueID6 521–529
A Hurria HB Muss HJ Cohen (2003) Cancer and Aging D Kufe (Eds) Holland-Frei Cancer Medicine BC Decker Hamilton 1093–1099
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hurria, A., Brogan, K., Panageas, K.S. et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 92, 151–156 (2005). https://doi.org/10.1007/s10549-005-1410-8
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-1410-8